يعرض 461 - 480 نتائج من 23,970 نتيجة بحث عن '(( significant ((small decrease) OR (linear increase)) ) OR ( significant decrease decrease ))', وقت الاستعلام: 0.52s تنقيح النتائج
  1. 461
  2. 462
  3. 463
  4. 464
  5. 465
  6. 466
  7. 467

    Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. حسب Luqiong Liu (11537092)

    منشور في 2024
    "…(<b>C</b>) Y-27632 collaborated with BA to alleviate the decrease in FD-4 flux in LPS-induced Caco2 cells on day 22. …"
  8. 468
  9. 469
  10. 470
  11. 471
  12. 472
  13. 473

    Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> حسب Razia Rashid Rahil (22772495)

    منشور في 2025
    "…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …"
  14. 474
  15. 475
  16. 476

    Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx حسب Tengxiang Zhao (20749475)

    منشور في 2025
    "…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…"
  17. 477

    Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx حسب Tengxiang Zhao (20749475)

    منشور في 2025
    "…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…"
  18. 478
  19. 479
  20. 480